Numerous ALK inhibitors have been developed, such as crizotinib, ceritinib, alectinib and brigatinib, and are used clinically for the treatment of patients with ALK-fusion positive tumors such as EML4-ALK positive non-small cell lung cancer (NSCLC)24,25. This evidence concerns the gene ALK and non-small cell lung carcinoma.